NL-OMON37895已完成不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE DOSE, SAFETY, TOLERABILITY PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF BCI 838 IN HEALTHY ADULT SUBJECTS - BCI-838 MAD study, tolerabilty, uptake and distribution study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male and female subjects
- •Age: 18 * 55 years, inclusive
- •BMI: 18 * 30 kg/m2, inclusive
- •Non smoker or moderate smoker (*5 cigarettes per day)
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study
研究者
相似试验
进行中（未招募）
1 期
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-GBF. Hoffmann-La Roche Ltd.129
进行中（未招募）
1 期
STUDY OF ECULIZUMAB IN REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)SUBJECTSMedDRA version: 16.1 Level: HLT Classification code 10071942 Term: Myasthenia gravis and related conditions System Organ Class: 100000004859Generalized Myasthenia GravisEUCTR2013-003589-15-GRAlexion Pharmaceuticals, Inc.125
进行中（未招募）
1 期
STUDY OF ECULIZUMAB IN REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)SUBJECTSMedDRA version: 17.0 Level: HLT Classification code 10071942 Term: Myasthenia gravis and related conditions System Organ Class: 100000004859Generalized Myasthenia GravisEUCTR2013-003589-15-GBAlexion Pharmaceuticals, Inc.125
已完成
4 期
A clinical study to assess the benefits of Concentrace Trace Mineral Drops-(CTMD®), a food supplement in subjects with OSTEOARTHRITIS (OA) of knee jointCTRI/2010/091/001105Dr. Himanshu Bansal100
进行中（未招募）
不适用
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-ESF. Hoffmann-La Roche Ltd.180